Debt-free Balance SheetZero reported debt reduces financial risk and preserves strategic optionality for a pre-commercial biotech. Over 2–6 months this durable low-leverage position helps the company pursue R&D, partnerships, or opportunistic financing without immediate interest burden, supporting program continuity.

Focused Nanomedicine PipelineOwning two differentiated, development-stage assets (MRI contrast and theranostic radionuclide) aligns with structural industry trends toward targeted diagnostics and theranostics. This focused pipeline increases partnership and commercialization options and concentrates R&D resources on high-impact programs.

Narrowing Net Losses TrendA consistent reduction in net losses over multiple years signals operational progress in cost control or program efficiency. Sustained narrowing reduces future financing needs and improves the company’s ability to extend runway or negotiate partnerships on stronger terms if the trend continues.

Bears Say

Persistent Operating Cash BurnMaterial negative operating cash flows indicate the company is cash-consuming and dependent on external capital to fund operations and trials. Over the medium term this constrains autonomy, increases financing and dilution risk, and could slow program timelines if fresh funding is delayed.

Volatile, Declining RevenueSharp, unpredictable revenue declines undermine the foundation for sustainable operations and suggest weak commercial traction or one-off receipts. Continued volatility increases reliance on external funding and limits reinvestment capacity, hindering long-term program and commercial development.

Eroding Equity And Negative ROEDeclining equity and sustained negative ROE indicate persistent value erosion from operating losses. This damages investor returns and can raise the cost of capital, making future fundraising more dilutive and potentially constraining strategic choices over the medium term.

SPAGO FAQ

What was Spago Nanomedical AB’s price range in the past 12 months?

Spago Nanomedical AB lowest stock price was kr0.06 and its highest was kr0.33 in the past 12 months.

What is Spago Nanomedical AB’s market cap?

Spago Nanomedical AB’s market cap is kr79.39M.

When is Spago Nanomedical AB’s upcoming earnings report date?

Spago Nanomedical AB’s upcoming earnings report date is May 07, 2026 which is in 79 days.

How were Spago Nanomedical AB’s earnings last quarter?

Currently, no data Available

Is Spago Nanomedical AB overvalued?

According to Wall Street analysts Spago Nanomedical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Spago Nanomedical AB pay dividends?

Spago Nanomedical AB does not currently pay dividends.

What is Spago Nanomedical AB’s EPS estimate?

Spago Nanomedical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Spago Nanomedical AB have?

Spago Nanomedical AB has 661,572,800 shares outstanding.

What happened to Spago Nanomedical AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Spago Nanomedical AB?

Currently, no hedge funds are holding shares in SE:SPAGO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Spago Nanomedical AB

Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.